INNOVATE (VATE) Q1 2025 earnings summary

Executive summary

• Q1 2025 consolidated revenue was $274.2M, down 13% year-over-year, mainly due to lower Infrastructure segment revenue, partially offset by strong Life Sciences growth, particularly from R2 Technologies.

• Net loss attributable to shareholders was $24.8M ($1.89/share), compared to $17.7M ($2.21/share) in Q1 2024, with the loss widening due to higher interest expense and equity method losses.

• Adjusted EBITDA was $7.2M, down from $12.8M in Q1 2024, reflecting lower Infrastructure earnings and higher Life Sciences losses.

• Infrastructure segment expanded adjusted backlog to $1.4B, adding over $500M in new awards.

• Substantial doubt exists about the company's ability to continue as a going concern due to upcoming debt maturities and cross-default provisions.

Financial highlights

• Infrastructure revenue decreased 14% to $264.9M, primarily due to project timing and completion of large projects.

• Life Sciences revenue increased 210% to $3.1M, driven by R2's strong sales growth and global expansion.

• Spectrum revenue was $6.2M, relatively stable year-over-year; Adjusted EBITDA was $1.4M.

• Cash and cash equivalents at March 31, 2025, were $33.3M, down from $48.8M at year-end 2024.

• Total principal outstanding indebtedness was $672M as of March 31, 2025.

Outlook and guidance

• DBM Global maintains a strong backlog of $1.4B and aims to convert it to revenue while pursuing new commercial and industrial opportunities.

• Life Sciences expects further growth from MediBeacon TGFR system and R2's international expansion.

• Spectrum segment anticipates commercial datacasting revenue by year-end 2025 and is preparing for ATSC 3.0 lighthousing.

• Management is exploring debt refinancing, asset sales, and capital raising to address liquidity and debt maturities.